Immutep Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Immutep Contact Number

Contact Immutep LAG3 & Cancer Immunotherapeutics

5 hours ago Immutep.com Show details

Thank you for your interest in Immutep and the cancer and autoimmune treatments made possible by our Lag-3 technology.For media requests, or to contact the Immutep team regarding partnerships, email [email protected]immutep.com and a member of our support team will direct your inquiry.

Category: Contact SupportShow more

LAG3 Effective Cancer Immunotherapy Immutep

4 hours ago Immutep.com Show details

What is LAG-3? Lymphocyte-activation gene 3, or LAG-3 (LAG-3), is a gene that provides the genetic information to make a cell surface molecule with biologic effects on T cell function. LAG-3 is being used for many immunotherapy treatments including Eftilagimod Alpha from Immutep.

Category: Contact NumberShow more

Immutep Shareholder Updates & Announcements

3 hours ago Immutep.com Show details

Request the Immutep Shareholder Newsletter below to receive updates and announcements by e-mail. Simply enter your name and email address, and select the authorization field to receive operational updates and select regulatory filings as they become available. Questions? Contact Immutep.

Category: Contact NumberShow more

Immunotherapeutics: Partnerships & Collaborations Immutep

8 hours ago Immutep.com Show details

Immutep owns the rights to the rest of the world. we have other collaborations with pharma, biotech and academia, e.g. LabCorp, MSD, Merck KGaA, Cytlimic, Monash University and University Hospital Pilsen. Other Collaborations: development of a LAG-3 depleting antibody (IMP731) in autoimmune diseases with GlaxoSmithKline;

Category: Contact NumberShow more

Immutep Crunchbase Company Profile & Funding

7 hours ago Crunchbase.com Show details

Phone Number +33169289992. Immutep is a biopharmaceutical company developing immunotherapeutics in oncology. Their products include a T cell immunostimulatory factor (APC activator) for cancer chemo-immunotherapy and a therapeutic antibody for immune response modulation in cancer. The Company's technologies are based on the LAG-3 immune control

Founder: Frédéric Triebel
Location: Sydney, New South Wales
Founded: Jul 01, 2007

Category: Contact NumberShow more

Immutep Help Center Frequently Asked Questions on LAG3

8 hours ago Immutep.com Show details

These preclinical results prompted Dr. Marek Nalos, Head Medical ICU at University Hospital Pilsen and the Nepean Hospital in Sydney, who was involved in preclinical infectious disease research with efti for a number of years, to ask Immutep to consider how efti could be applied to treat COVID-19 patients.

Category: Contact NumberShow more

LAG3 Immunotherapy Treatments: Cancer & Autoimmune …

4 hours ago Immutep.com Show details

Immutep is leading the development of immunotherapy for cancer and autoimmune diseases. Leadership in LAG-3 Immunotherapy We are global leaders in the understanding and development of therapeutics that relate to Lymphocyte Activation Gene-3 or "LAG-3” which is a cell surface molecule that plays a vital role in regulating the immune system.

Category: Contact NumberShow more

Immutep Company Profile Office Locations, Competitors

4 hours ago Craft.co Show details

Immutep has 1.73k Twitter Followers. The number of followers has increased 0.5% month over month and increased 3.1% quarter over quarter

Category: Contact NumberShow more

Immutep Limited Home Facebook

3 hours ago Facebook.com Show details

Immutep Limited. July 5 at 4:39 PM ·. Immutep Limited has completed all the necessary competent authority steps with the US FDA to commence its phase IIb TACTI-003 trial in the United States. “We are delighted to start our new TACTI-003 trial in 1st line HNSCC patients to evaluate efti in combination with pembrolizumab vs pembrolizumab

Category: Home PhoneShow more

Immutep Limited LinkedIn

3 hours ago Au.linkedin.com Show details

Immutep Limited 1,805 followers on LinkedIn. The global leader in developing LAG-3 therapeutics Immutep is a globally active biotechnology company, listed on the Australian Stock Exchange and on the NASDAQ Global Market in the US. As a leader in personalized bio-therapeutic products for cancer, Immutep is dedicated to leveraging its current technology and expertise to develop innovative

Category: Contact NumberShow more

Institutions Support Immutep Capital Raising – ShareCafe

5 hours ago Sharecafe.com.au Show details

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) is pleased to announce it has completed the second tranche of its institutional placement (Placement), details of which were announced to the market on 21 June 2021.The second tranche of the Placement comprises the issue of 88,970,717 new ordinary fully paid shares in the Company (Tranche 2 Shares) at an issue …

Category: Support NumberShow more

EX99.1

4 hours ago Sec.gov Show details

406 759 268

Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease. Further information can be found on the Company’s website www.immutep.com or by contacting: For further information please visit www.immutep.com or contact: Australian Investors/Media: Catherine Strong, Citadel-MAGNUS +61 (0)406 759 268; [email protected]

Category: Contact NumberShow more

Immutep Limited (IMMP) Company Profile & Facts Yahoo Finance

5 hours ago Finance.yahoo.com Show details

See the company profile for Immutep Limited (IMMP) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their

Category: Contact NumberShow more

EX99.1

4 hours ago Sec.gov Show details

(917) 860-9404

Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the U.S. For further information, please visit www.immutep.com or contact: U.S. Investors: Jay Campbell, Vice President of Business Development and Investor Relations, Immutep Limited +1 (917) 860-9404; [email protected]immutep.com. Australian Investors/Media:

Category: Contact NumberShow more

Australian Ethical On Emerging Biotech Company Immutep

2 hours ago Sharecafe.com.au Show details

Immutep Ltd (ASX:IMM) is a biotechnology company that engages in the research, development, and commercialization of biological products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Key points in the video: Immutep is at the forefront of the emerging field of cancer immunotherapy.

Category: Tech SupportShow more

Immutep ASX Announcements

2 hours ago Immutep.com Show details

Immutep Completes Recruitment for Part A of TACTI-002 trial. 3. PDF. 22/06/2020. ! Immutep receives A$1,437,826 R&D Tax Incentive. 2. PDF. 01/06/2020.

Category: Contact NumberShow more

Immutep Wikipedia

2 hours ago En.wikipedia.org Show details

Immutep Ltd (formerly Prima Biomed) is a biotechnology company working primarily in the field of cancer immunotherapy using the LAG3 immune control mechanism. The company was originally built on CVac, a therapeutic cancer vaccine.In late 2014 the privately held French immunotherapy company Immutep SA was purchased by Prima Biotech.

Category: Contact NumberShow more

What Type Of Shareholders Own The Most Number of Immutep

2 hours ago Ca.finance.yahoo.com Show details

I can report that insiders do own shares in Immutep Limited. As individuals, the insiders collectively own AU$13m worth of the AU$286m company. It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying. General Public Ownership. The general public -- including retail investors -- own 51% of

Category: Contact NumberShow more

Immutep Limited (IMMP) Company Profile & Overview Stock

6 hours ago Stockanalysis.com Show details

Company profile for Immutep Limited (IMMP) with a description, list of executives, contact details and other key facts. Company profile for Immutep Limited (IMMP) with a description, list of executives, contact details and other key facts. CUSIP Number: 45257L108: ISIN Number: US45257L1089: Key Executives. Name Position;

Category: Contact NumberShow more

What Type Of Shareholders Own The Most Number of Immutep

9 hours ago Finance.yahoo.com Show details

We note that hedge funds don't have a meaningful investment in Immutep. Our data shows that BNY Mellon Asset Management is the largest shareholder with 36% of shares outstanding. Meanwhile, the

Category: Contact NumberShow more

Immutep Funding, Financials, Valuation & Investors

6 hours ago Crunchbase.com Show details

Funding. Immutep has raised a total of A$16.9M in funding over 2 rounds. Their latest funding was raised on Jul 9, 2019 from a Post-IPO Equity round. Immutep is registered under the ticker NASDAQ:IMMP . Immutep is funded by 3 investors. Australian Ethical Investment and …

Category: Contact NumberShow more

Immutep : ESMO 2021 – INSIGHT Stratum D Poster

1 hours ago Marketscreener.com Show details

Immutep Ltd. published this content on 20 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and …

Category: Contact NumberShow more

Immutep Company Profile: Stock Performance & Earnings

7 hours ago Pitchbook.com Show details

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its lead product is IMP321, which involves in clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti

Category: Contact NumberShow more

Immutep : goetzpartners securities Door reopens to

5 hours ago Marketscreener.com Show details

Immutep is developing immunotherapies for cancer, with a focus on the immune checkpoint LAG-3. The immune checkpoint inhibitor ("ICI") class has experienced rapid adopon since the launch of BMS's Yervoy (ipilimumab) in 2011, owing to their ability to elicit durable responses in 20 - 50% of paents for up to 10 years.

Category: Contact NumberShow more

Karl Pechmann Chief Financial Officer and Company

9 hours ago Au.linkedin.com Show details

A number of our products have been partnered with large pharmaceutical partners including Novartis, GSK, Eddingpharm and Neopharm. Immutep is listed on the Australian Stock Exchange and on the NASDAQ Global Market in the US (ADR's). Show more Show less

Title: Chief Financial Officer and …
Location: Greater Sydney
1. 500+ connections

Category: Contact NumberShow more

Immutep Reports Statistically Significant Survival Benefit

6 hours ago Finance.yahoo.com Show details

Additional LAG-3 products, including antibodies for immune response modulation, are being developed by Immutep’s large pharmaceutical partners.Further information can …

Category: Contact NumberShow more

Biotech Immunotherapy Company Immutep Sets the Standard

8 hours ago Finance.yahoo.com Show details

Immutep was one of the Benzinga Biotech Small Cap Conference held virtually on March 24 & 25, 2021. The information contained in this article …

Category: Tech SupportShow more

Immutep : to Present Data, Trial Design of Clinical

Just Now Marketscreener.com Show details

Immutep : to Present Data, Trial Design of Clinical Studies for Cancer Treatments During Medical Conference; Shares Down 3% 10/04/2021 03:13am EDT Send by mail :

Category: Contact NumberShow more

Immutep Quarterly Activities Report Yahoo

1 hours ago Finance.yahoo.com Show details

The net cash used in Research and Development activities in the quarter was $1.74 million, compared to $3.18 million in Q2. Year to date cash flow used in R&D activities for the 9 …

Category: Contact NumberShow more

Buy Immutep Limited (IMMP) today, based on longterm

2 hours ago Baxterreport.com Show details

The total number of common shares currently owned by the public is 64.87 million. IMMP does have institutional investors; and they hold 7.20% of the stock. Immutep Limited – Insider Activity and Holdings. Currently, the stock has been recommended as Strong Buy by 4 of the brokerage firms.

Category: Contact NumberShow more

Eric PujadeLauraine, Member, Clinical Advisory Board at

9 hours ago Relationshipscience.com Show details

Number of Boards. 2. Relationships. with RelSci Contact Aggregator. Empower Your Business Applications with Industry-Leading Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. Its product is IMP321, which involves in clinical

Category: Contact NumberShow more

How Do Analysts Feel About Immutep Limited (IMMP)? – The

4 hours ago Baxterreport.com Show details

IMMP – Immutep Limited Stock Earnings Estimates. Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is …

Category: Contact NumberShow more

IMMP Stock quote for IMMUTEP LIMITED MSN Money

4 hours ago Msn.com Show details

Benzinga.com 8/5/2021. Immutep Reports Dosing of First Patient for Triple Combination (efti + anti-PD-1 + chemo) in INSIGHT-003. Stockhouse …

Category: Contact NumberShow more

Is Immutep Limited (IMMP) A Good Stock To Buy?

7 hours ago Finance.yahoo.com Show details

Of the funds tracked by Insider Monkey, Eversept Partners, managed by Kamran Moghtaderi, holds the number one position in Immutep Limited (NASDAQ:IMMP).Eversept Partners has a …

Category: Contact NumberShow more

Buy Immutep Limited (IMMP) today, based on longterm

Just Now Baxterreport.com Show details

The total number of common shares currently owned by the public is 64.87 million. IMMP does have institutional investors; and they hold 7.20% of the stock. Immutep Limited – Insider Activity and Holdings. Currently, the stock has been recommended as Strong Buy by 5 of the brokerage firms.

Category: Contact NumberShow more

What Are Analyst Opinions Regarding Immutep Limited (IMMP

5 hours ago Baxterreport.com Show details

The total number of common shares currently owned by the public is 64.87 million. IMMP does have institutional investors; and they hold 7.20% of the stock. Immutep Limited – Insider Activity and Holdings. Currently, the stock has been recommended as Strong Buy by 5 of the brokerage firms.

Category: Contact NumberShow more

Immutep Announces European Patent Grant For LAG525

5 hours ago Finance.yahoo.com Show details

About IMP701 and LAG525 IMP701 is a therapeutic antibody originally developed by Immutep S.A. (now Immutep S.A.S.) to target LAG-3. This antagonist antibody plays a …

Category: Contact NumberShow more

Immutep : Receives A$3.4 million R&D Tax Incentive from

4 hours ago Marketscreener.com Show details

SYDNEY, AUSTRALIA, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce it has received a €2,126,617 (~ A$3,430,952) research and development (R&D) tax incentive payment in …

Category: Contact NumberShow more

Immutep : Receives $2.5 Million Tax Incentive from France

7 hours ago Marketscreener.com Show details

Mean consensus: BUY: Number of Analysts: 3: Last Close Price: 0,53 AUD : Average target price: 1,18 AUD : Spread / Average Target

Category: Contact NumberShow more

Immutep Limited (IMMP) Dividend History, Dates & Yield

7 hours ago Stockanalysis.com Show details

IMMP News. 1 week ago - Immutep Receives A$3.4 million R&D Tax Incentive from French Government - ; GlobeNewsWire; 2 weeks ago - Immutep to Present Final Overall Survival Data From Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021 - ; GlobeNewsWire; 1 month ago - Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002 - ; …

Category: Contact NumberShow more

Immutep : Completes Recruitment of 2nd line PD1/PDL1

9 hours ago Marketscreener.com Show details

406 759 268

Further information can be found on the Company's website www.immutep.com or by contacting: Australian Investors/Media: Catherine Strong, Citadel-MAGNUS +61 (0)406 759 268; [email protected] Immutep Limited, Level 12, 95 Pitt Street, Sydney NSW …

Category: Contact NumberShow more

Immutep Taking the Fight to Cancer – ShareCafe

5 hours ago Sharecafe.com.au Show details

Immutep (ASX: IMM) is a global leader in the understanding and development of therapeutics that modulate Lymphocyte Activation Gene-3 or “LAG-3” which is a cell surface molecule which plays a vital role in regulating T cells. LAG-3 was discovered by Immutep’s Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel, putting

Category: Contact NumberShow more

Immutep Limited (IMMP): The stock short term indicators

3 hours ago Baxterreport.com Show details

The total number of common shares currently owned by the public is 64.87 million. IMMP does have institutional investors; and they hold 7.20% of the stock. Immutep Limited – Insider Activity and Holdings. Currently, the stock has been recommended as Strong Buy by 4 of the brokerage firms.

Category: Contact NumberShow more

Don’t Fear the Taper – ShareCafe

Just Now Sharecafe.com.au Show details

5 hours ago · The taper – which was first hinted at in a speech by Ben Bernanke on 22 May 2013 – set a clear path to the end of QE and led to the first post-GFC rate increase in December 2015. The data clearly shows a ‘dovish’ Federal Reserve tended to be good for stocks over the following week and month (on average up +1.53% and +3.52% respectively).

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

What kind of a company is immutep limited?

Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases.

How much money has immutep raised to date?

Immutep secures commitments for A$60 million through a two-tranche institutional placement to expand its clinical development and manufacturing program into late-stage settings Whats next. About us. passion. It takes a great deal of passion to pursue the fight against cancer and autoimmune diseases.

What is the objective of immunotherapy company immutep?

Immutep’s objective is to harness and strengthen the power of the body’s own immune system through therapeutic intervention for the benefit of patients’ health — and how immunotherapy fights cancer and autoimmune diseases.

When did immutep limited change its name from prima biomed?

The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia. Immutep Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Brand New Updated

Popular Brands

Intel
Icbc
Imcd
Iqvia
Idex
Isbank
Ing
Intuit
Itc
Ipg